Skip to content
10-Q/A

Quarterly Report

Ibere Pharmaceuticals

0001104659-21-106486

← back to feed
Filed
Aug 16, 2021 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$446.73K
Short Term Debt Q1 2021 · Mar 31, 2021 $0
Cash And Equivalents Q1 2021 · Mar 31, 2021 $1.22M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $175.37K
Stockholders Equity restated Q1 2021 · Mar 31, 2021 −$12.8M
Stockholders Equity Q1 2021 · Dec 31, 2020 $19.24K
Current Liabilities Q1 2021 · Mar 31, 2021 $395.93K
Current Liabilities Q1 2021 · Dec 31, 2020 $657.13K
Total Liabilities restated Q1 2021 · Mar 31, 2021 $14.43M
Total Liabilities Q1 2021 · Dec 31, 2020 $657.13K
Current Assets Q1 2021 · Mar 31, 2021 $1.63M
Current Assets Q1 2021 · Dec 31, 2020 $175.37K
Total Assets Q1 2021 · Mar 31, 2021 $139.63M
Total Assets Q1 2021 · Dec 31, 2020 $676.37K
Net Income restated Q1 2021 · Mar 31, 2021 −$405.7K
Operating Income Q1 2021 · Mar 31, 2021 −$94.48K